Clinical Trials for Ovarian Cancer

A Phase 1a/b Study to Evaluate the Safety and Efficacy of OPB-101, an Autologous Mesothelin (MSLN) CAR T Cell Therapy With Antigen-dependent Expression of OUTSMART™ Designed IL-2 Cytokine in Platinum-resistant Ovarian Cancer

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Single-arm study in adults with platinum-resistant high-grade serous ovarian, fallopian tube, or primary peritoneal cancer (ECOG 0–1, measurable disease, ≥2 prior lines, PARPi if BRCA1/2+) receiving OPB-101, an autologous mesothelin-directed CAR T cell therapy with antigen-dependent OUTSMART IL-2/15 cytokine expression and an EGFR-based safety switch. Evaluates dose escalation/expansion to define safety and RP2D.

ClinicalTrials.gov ID: NCT07030907

A Phase I Clinical Trial of an Infusion of Autologous T Cells Genetically Engineered With a Chimeric Receptor to Target the Follicle-Stimulating Hormone Receptor in Patients With Recurrent Ovarian Cancer

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with recurrent or persistent epithelial ovarian, fallopian tube, primary peritoneal, or select sex cord-stromal tumors (platinum-resistant/refractory after ≥1 platinum and ≥2 prior systemic regimens; measurable/detectable disease; ECOG 0–2) receive a single infusion of autologous T cells engineered with a chimeric endocrine receptor targeting FSHR, delivered intraperitoneally or intravenously across escalating dose levels. Investigational product: FSHR-targeted CAR-like T cells designed for antigen-directed activation/cytotoxicity against FSHR-expressing tumors.

ClinicalTrials.gov ID: NCT05316129

The Efficacy of T-regulatory Cell Depletion with E7777 Combined with Immune Checkpoint Inhibitor, Pembrolizumab, in Recurrent or Metastatic Solid Tumors: Phase I/II Study

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with recurrent/metastatic solid tumors that progressed on standard therapy (Phase I: pembrolizumab-appropriate tumors; expansion: platinum-resistant ovarian cancer without prior PD-1/PD-L1 and MSI-H cancers post–PD-1/PD-L1) receive pembrolizumab plus E7777 (denileukin diftitox), a CD25-directed IL-2–diphtheria toxin fusion that depletes T-regulatory cells. E7777 is given days 1–3 of 21-day cycles (dose-escalation to RP2D, up to 8 cycles) with fixed-dose pembrolizumab, continuing until progression/toxicity.

ClinicalTrials.gov ID: NCT05200559

An Open-Label, Phase 1 Study to Evaluate Safety, Tolerability and Pharmacokinetics of the CTPS1 Inhibitor STP938 in Adult Subjects With Advanced Solid Tumors, With a Safety Expansion in Advanced CTPS2 Null Ovarian Cancer

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced solid tumors refractory to standard therapy receive oral STP938 (dencatistat), a first‑in‑class selective CTPS1 inhibitor, in dose escalation; a safety expansion enrolls patients with CTPS2-null ovarian cancer to exploit a synthetic-lethal vulnerability. Key exclusions include active CNS disease and significant immunosuppression.

ClinicalTrials.gov ID: NCT06297525

Phase II Study of ONC201 Plus Weekly Paclitaxel in Patients With Platinum-Resistant Refractory or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Single-arm study for adults with platinum-resistant or refractory epithelial ovarian, fallopian tube, or primary peritoneal cancer (measurable disease, ECOG 0–1; prior lines allowed) testing weekly paclitaxel plus oral ONC201 (dordaviprone), an investigational DRD2/3 antagonist that activates the integrated stress response and inhibits Akt/ERK signaling, with ONC201 continuation permitted if paclitaxel stops. Evaluates safety and preliminary efficacy (ORR/PFS), with PK/PD and immune correlatives.

ClinicalTrials.gov ID: NCT04055649

A Phase 1/1b Dose Escalation Study of Abemaciclib and Olaparib for Recurrent Platinum-Resistant Ovarian Cancer

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Single-arm study for adults with recurrent platinum-resistant epithelial ovarian cancer (1–3 prior lines; ECOG 0–2), including prior frontline PARP inhibitor but no prior CDK4/6 inhibitor; dose-expansion limited to high-grade serous disease with biopsy-accessible tumors. Patients receive continuous olaparib (PARP inhibitor) plus abemaciclib (CDK4/6 inhibitor causing G1 arrest) to evaluate safety and preliminary activity of this combination based on proposed synthetic lethality and replication-stress synergy.

ClinicalTrials.gov ID: NCT04633239

Randomized Phase 2 Trial of APL-2 With Pembrolizumab vs. APL-2 With Pembrolizumab and Bevacizumab vs. Bevacizumab Alone in Patients With Recurrent Ovarian Cancer and Persistent Malignant Effusion

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer and symptomatic malignant ascites/pleural effusion (ECOG 0–1; prior therapies and platinum sensitivity unrestricted) are randomized to pegcetacoplan (C3 complement inhibitor) plus pembrolizumab with or without bevacizumab versus bevacizumab alone. Aims include reducing effusion burden and assessing antitumor activity; key exclusions include active autoimmune disease requiring treatment, recent immunosuppression, recent checkpoint inhibitor, uncontrolled CV disease, and active HBV/HCV viremia.

ClinicalTrials.gov ID: NCT04919629

A Phase 1b Study of BCL-XL Degrader DT2216 in Combination With Weekly Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with platinum‑resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (RECIST‑measurable; up to 4 prior lines; excludes prior weekly paclitaxel/BCL‑XL inhibitors) receive weekly paclitaxel plus DT2216, a VHL‑recruiting PROTAC that degrades BCL‑XL to induce apoptosis with reduced platelet toxicity. Single‑arm dose‑finding evaluates safety/tolerability and preliminary activity; key exclusions include active CNS disease, significant effusions/obstruction, and strong CYP3A4/2C8 modulators.

ClinicalTrials.gov ID: NCT06964009

A First-in-human, Phase I, Multi-center, Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Evidence of Antitumor Activity of IDOV-Immune in Adult Participants With Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced solid tumors refractory to standard therapy (ECOG 0–1, measurable disease) receive a single intravenous infusion of IDOV-Immune (VM-002), a genetically engineered oncolytic vaccinia virus designed for tumor-selective replication and lysis with immune-stimulating transgenes to enhance antitumor immunity. Key exclusions include prior oncolytic virus therapy, recent vaccinia/smallpox vaccination, active autoimmune disease requiring systemic therapy, significant cardiopulmonary disease, uncontrolled infection, and unstable/untreated CNS metastases.

ClinicalTrials.gov ID: NCT06910657

A Dose Escalation and Dose Optimization Phase 1a/1b Study to Evaluate Safety, Tolerability and Dosimetry of Radioligand Therapy With LY4337713 in Adults With FAP-Positive Solid Tumors (FiREBOLT)

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced/metastatic FAP-expressing solid tumors (including pancreatic, multiple breast cancer subtypes, platinum-resistant/refractory ovarian, and other FAP-positive GI tumors) and ECOG 0–1 receive intravenous LY4337713, a lutetium-177–labeled small-molecule radioligand targeting fibroblast activation protein on cancer-associated fibroblasts to deliver beta radiation to the tumor microenvironment, on Q4–6 week cycles. Expansion cohorts are tumor-specific after dose escalation/optimization.

ClinicalTrials.gov ID: NCT07213791